表紙
市場調查報告書

焦點市場分析:神經內分泌腫瘤(NET)

Market Spotlight: Neuroendocrine tumors (NET)

出版商 Datamonitor Healthcare 商品編碼 939993
出版日期 內容資訊 英文 43 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:神經內分泌腫瘤(NET) Market Spotlight: Neuroendocrine tumors (NET)
出版日期: 2020年04月30日內容資訊: 英文 43 Pages
簡介

Datamonitor Healthcare推定2019年世界約發生531,400件神經內分泌腫瘤(NET)病例,預計其數至2028年增加到639,200件。2019年的NET的大部分,是惡性類癌症或神經內分泌腫瘤。

本報告提供神經內分泌腫瘤(NET)的主要上市藥、開發平台藥物,近幾年的動向和分析師的見解,臨床試驗,成功的可能性,不久將來的動向、規定趨勢,專利資訊,10年的發生率預測,授權、資產取得交易,及各類醫藥品的收益預測等相關分析。

概要

要點

疾病的背景

  • 各子類型

治療

  • 手術
  • 肝動脈栓塞術
  • 生長抑制素類似體
  • α干擾素(IFN-Alpha)
  • 化療
  • 放射治療
  • 標靶治療
  • 緩和照護

流行病學

  • 發生率的調查手法
  • 疾病定義
  • 盛行率的調查手法

上市藥

開發平台藥物

近幾年的動向、分析師的見解

  • TBR-760

主要的法規動向

  • RadioMedix,優先考慮PET診斷藥
  • University of Iowa的PET中心取得NME核准

成功概率

授權、資產收購交易

本源專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:各階段
  • 近幾年的動向

文件

附錄

目錄
Product Code: DMKC0184311

This Market Spotlight report covers the Neuroendocrine Tumors market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, probability of success, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2019, there were approximately 531,400 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 639,200 incident cases by 2028. Worldwide, the majority of NETs in 2019 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, and tryptophan hydroxylase. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation
  • The majority of industry-sponsored drugs in active clinical development for NETs are in Phase I. Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are administered intravenously, with the remainder being oral, subcutaneous, intranasal, and intratumoral formulations.
  • The overall likelihood of approval of a Phase I solid tumors asset is 5.6%, and the average probability a drug advances from Phase III is 42.5%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
  • There have been only seven licensing and asset acquisition deals involving NET drugs during 2015-20. The $115m exclusive licensing agreement signed in November 2017 between NanoCarrier and VBL Therapeutics for the development, commercialization, and supply of VB-111 in Japan was the only deal with a disclosed value.
  • The distribution of clinical trials across Phase I-IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 77% of trials in Phase I-II, and only 23% in Phase III-IV.
  • The US has a substantial lead in the number of NET clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.
  • Novartis has the highest number of completed clinical trials for NETs, with 19 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for NETs, followed by Ipsen.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Hepatic artery embolization
  • Somatostatin analogs
  • Interferon-alpha (IFN-alpha)
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
  • Palliative care

EPIDEMIOLOGY

  • Incidence methodology
  • Disease definition
  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • TBR-760 for NETs (January 3, 2019)

KEY REGULATORY EVENTS

  • RadioMedix Eyes Priority Review For PET Diagnostic Agent
  • University of Iowa PET Center Earns NME Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of NETs, 2019-28
  • Figure 2: Incident cases of NETs, by tumor type, 2019
  • Figure 3: Overview of pipeline drugs for NETs in the US
  • Figure 4: Pipeline drugs for NETs, by company
  • Figure 5: Pipeline drugs for NETs, by drug type
  • Figure 6: Pipeline drugs for NETs, by classification
  • Figure 7: Probability of success in the NETs pipeline
  • Figure 8: Licensing and asset acquisition deals in NETs, 2015-20
  • Figure 9: Parent patents in NETs
  • Figure 10: Clinical trials in NETs
  • Figure 11: Top 10 drugs for clinical trials in NETs
  • Figure 12: Top 10 companies for clinical trials in NETs
  • Figure 13: Trial locations in NETs
  • Figure 14: NETs trials status
  • Figure 15: NETs trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of NETs, 2019-28
  • Table 2: Five-year prevalent cases of NETs, 2019-28
  • Table 3: Marketed drugs for NETs
  • Table 4: Pipeline drugs for NETs in the US
  • Table 5: TBR-760 for NETs (January 3, 2019)
  • Table 6: Historical global sales, by drug ($m), 2014-18
  • Table 7: Forecasted global sales, by drug ($m), 2020-24